Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development

• Published in: Daru 2024-09, Vol.32 (2), p.907-924
• Main Authors: Padhy, Ipsa, Sharma, Tripti, Banerjee, Biswajit, Mohapatra, Sujata, Sahoo, Chita R., Padhy, Rabindra Nath
• Format: Article
• Language: English
• Subjects: Amino acids; Animals; Anti-Obesity Agents - chemistry; Anti-Obesity Agents - pharmacology; Biomedical and Life Sciences; Biomedicine; Carbonates; Carbonic Anhydrase Inhibitors - chemistry; Carbonic Anhydrase Inhibitors - pharmacology; Carbonic Anhydrases - chemistry; Carbonic Anhydrases - metabolism; Drug Development; Drug therapy; Fatty acids; Humans; Liraglutide; Lorcaserin; Medicinal Chemistry; Metabolism; Mitochondria - drug effects; Mitochondria - enzymology; Obesity; Obesity - drug therapy; Obesity - enzymology; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Physiological aspects; Review Article; Structure-Activity Relationship; Sulfonamides; Synthesis
• ISSN: 2008-2231; 1560-8115; 2008-2231
• DOI: 10.1007/s40199-024-00535-w

Background Obesity has emerged as a major health challenge globally in the last two decades. Dysregulated fatty acid metabolism and de novo lipogenesis are prime causes for obesity development which ultimately trigger other co-morbid pathological conditions thereby risking life longevity. Fatty acid metabolism and de novo lipogenesis involve several biochemical steps both in cytosol and mitochondria. Reportedly, the high catalytically active mitochondrial carbonic anhydrases (CAVA/CAVB) regulate the intercellular depot of bicarbonate ions and catalyze the rapid carboxylation of pyruvate and acetyl-co-A to acetyl-co-A and malonate respectively, which are the precursors of fatty acid synthesis and lipogenesis. Several in vitro and in vivo investigations indicate inhibition of mitochondrial carbonic anhydrase isoforms interfere in the functioning of pyruvate, fatty acid and succinate pathways. Targeting of mitochondrial carbonic anhydrase isoforms (CAVA/CAVB) could thereby modulate gluconeogenetic as well as lipogenetic pathways and pave way for designing of novel leads in the development pipeline of anti-obesity medications. Methods The present review unveils a diverse chemical space including synthetic sulphonamides, sulphamates, sulfamides and many natural bioactive molecules which selectively inhibit the mitochondrial isoform CAVA/CAVB with an emphasis on major state-of-art drug design strategies. Results More than 60% similarity in the structural framework of the carbonic anhydrase isoforms has converged the drug design methods towards the development of isoform selective chemotypes. While the benzene sulphonamide derivatives selectively inhibit CAVA/CAVB in low nanomolar ranges depending on the substitutions on the phenyl ring, the sulpamates and sulpamides potently inhibit CAVB. The virtual screening and drug repurposing methods have also explored many non-sulphonamide chemical scaffolds which can potently inhibit CAVA. Conclusion The review could pave way for the development of novel and effective anti-obesity drugs which can modulate the energy metabolism. Graphical abstract